Though PD-1/PDL-1 and CTLA-4 checkpoint blockades have dominated the clinical development of immune therapy for cancer, there has long been the appreciation that these are not the only proteins that function as immune checkpoints in human biology. Here, CTLA4 is linked to cancer.